CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...

Funding Agency:
Merck, Sharp & Dohme
Period: 1992-1993
Grant Title: MK-906 Early Intervention-Second Open Extension (Months 25-36)
Funding Agency:
Cellcor Corporation
Period: 1991
Grant Title:
Autolymphocyte Therapy for Node Positive Renal Cell Carcinoma
Funding Agency:
Smith Kline Beecham
Period: 1991
Grant Title:
Effect of SKF105657 on Prostate and Serum DHT Levels
Funding Agency:
Merck, Sharp & Dohme
Period: 1992-1993
Grant Title:
Prostatic Testosterone Dihydrotestosterone Tissue Levels After Therapy with
MK-434
Funding Agency:
Sterling Research Group
Period: 1993
Grant Title:
A Phase II Dose-Ranging, Safety and Efficacy Study of Oral Zanoterone
Administered Daily as Primary Hormonal Therapy in Subjects with Stage D2
Prostate Cancer
Funding Agency:
Merck, Sharp & Dohme Research Laboratories
Period: 1991
Grant Title:
MK-906 Early Intervention Medical Therapy for BPH Extension Study
Funding Agency:
Berlex Labs
Period: 1991
Grant Title:
Atamestane Therapy for Benign Prostatic Hyperplasia
Funding Agency:
Sterling Research Group
Period: 1992
Grant Title:
A Phase II Dose-Ranging Efficacy Study of Oral Zanoterone, A New Steroidal
Androgen Receptor Antagonist, in Men with Symptomatic Benign Prostatic
Hyperplasia
Funding Agency:
Smith Kline Beecham Pharmaceuticals
Period: 1992
Grant Title:
A One-Year, Multicenter, Double-Blind Comparison of the Effects of
Once- Daily dosing with Three Dose Levels of SK&F 105657 or Placebo in the
Treatment of Symptomatic Benign Prostatic Hyperplasia with Six-Month
Untreated Follow-Up
Funding Agency:
ICI Pharmaceuticals
Period: 1992
Grant Title:
A Randomized, Comparative Trial of Casodex Versus Flutamide Used in
Combination with Medical Castration in Patients with Untreated Metastatic
Prostate Cancer
Funding Agency:
Merck, Sharp & Dohme
Period: 1992 - 1996
6